FDA study finds pharmacy drug info insufficient

Share this article:

A new FDA study found that printed consumer medication information – the literature accompanying a dispensed prescription drug – does not sufficiently educate consumers about the use and risks of the medication.

The studyExpert and Consumer Evaluation of Consumer Medical Information, found that 94% of consumers received the information with their prescriptions, but that only 75% of this information (dubbed "CMI" by the agency) met criteria for usefulness.

That criterion (established by a steering committee including healthcare professionals, consumer groups, pharma manufacturers, and others) was set after Congress enacted a law in 1996 requiring the private sector to distribute useful CMI with 95% of all new prescriptions by 2006. The 1996 criteria for useful CMI called for the materials to be scientifically accurate, unbiased, specific and comprehensive, understandable, timely, and useful. In 2001, FDA updated the criteria to include more specific CMI requirements, such as drug name, use, contraindications and frequent adverse reactions, among others.

“The current voluntary system has failed to provide consumers with the quality information they need in order to use medicines effectively and safely,” said Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, in a statement.

FDA has created a website to receive public comment on the study, and to solicit feedback from consumers regarding the best ways to provide useful CMI.

In July, the National Consumers League filed a petition with the FDA asking the agency to consolidate the materials consumers receive with a prescription drug, and provide a single, concise document.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...